BioSpace News Archive

Over 480 million people worldwide likely suffer from chronic obstructive pulmonary disease, or COPD, according to a late-breaking abstract led by ResMed presented at the European Respiratory Society Congress.

Fresenius Kabi and AABB announced the official start of the 17th annual Blood Collectors Week celebration, which runs September 4-10, 2022.

Leap Therapeutics, Inc. announced the Company will be presenting data in first-line patients with advanced gastroesophageal adenocarcinoma from the DisTinGuish study, a Phase 2a clinical trial evaluating Leap’s anti-Dickkopf-1 antibody, DKN-01, in combination with tislelizumab, BeiGene’s anti-PD-1 antibody, and chemotherapy, at the European Society for Medical Oncology Congress 2022 being held on September 9-12.

POINT Biopharma Global Inc., a company accelerating the discovery, development, and global access to life-changing radiopharmaceuticals, announced data will be released at ESMO Congress 2022 in Paris, France about the efficacy and safety of PNT2002 in the lead-in cohort of the SPLASH trial.

Blade Therapeutics, Inc., a clinical-stage biopharmaceutical company developing cutting-edge treatments for debilitating fibrotic and neurodegenerative diseases, announced the presentation of positive data from Phase 1 and preclinical studies of cudetaxestat, an investigational non-competitive autotaxin inhibitor in clinical development for IPF and other fibrotic diseases.

Affimed N.V. announced that an abstract with clinical trial results of its innate cell engager AFM24 has been accepted for a poster presentation at the Congress of the European Society for Medical Oncology from 9-13 September 2022 in Paris.

Zymeworks Inc., a clinical-stage biopharmaceutical company developing multifunctional biotherapeutics, announced the release of an abstract by ESMO with preliminary results from the company’s Phase 1 study of zanidatamab zovodotin, an investigational novel bispecific HER2 targeted antibody-drug conjugate.

Regeneron Pharmaceuticals, Inc. announced that new and updated data across its oncology pipeline will be presented at the European Society for Medical Oncology Congress 2022 from September 9 to 13 in Paris.

Innovent Biologics, Inc. announces that the first participant has been successfully dosed in the higher-dose cohort of a phase 2 clinical trial of mazdutide, a glucagon-like peptide 1 receptor and glucagon receptor dual agonist, in Chinese adults with obesity.

Gilead Sciences, Inc. announced new data from a post hoc subgroup analysis from the Phase 3 TROPiCS-02 study evaluating Trodelvy® versus comparator chemotherapies in patients with HR+/HER2- metastatic breast cancer who progressed on endocrine-based therapies and at least two chemotherapies.